JAK
Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.
-
A3339 CYT387 sulfate saltSummary: JAK1/JAK2 inhibitor
-
A3514 JAK2 Inhibitor V, Z3Summary: Jak2 tyrosine kinase inhibitor
-
A3515 JANEX-1Summary: JAK3 inhibitor
-
A3675 NVP-BSK805Summary: ATP-competitive JAK2 inhibitor
-
A3741 Pyridone 6Target: JAKSummary: Pan-JAK inhibitor
-
A3781 Ruxolitinib phosphateSummary: JAK1/JAK2 inhibitor
-
A3794 SB1317Summary: CDK,JAK and FLT inhibitor
-
A3936 WHI-P97Summary: Janus kinase (JAK)-3 inhibitor
-
A3937 XL019Target: JAKSummary: JAK2 inhibitor,potent and selective
-
A4147 LY2784544Target: Aurora Kinases|FLT3|VEGFR|FGFR|Trk Receptors|JAK|ALK|TYK2|MUSK|MAP3KSummary: JAK2 inhibitor,highly potent and selective